Glioblastoma: Looking at the currently marketed sigma-1 agonists and antagonists

Neoplasia

Volumn 9, Issue 8, 2007, Pages 689-

  Kast, Richard E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; FLUVOXAMINE; HALOPERIDOL; MEMANTINE; SIGMA 1 OPIATE RECEPTOR;

APOPTOSIS; BREAST CANCER; CELL MOTILITY; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; LETTER; PRIORITY JOURNAL;

EID: 34548214224     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07451     Document Type: Letter

References (10)

1. Megalizzi V, Mathieu V, Mijatovic T, Gailly P, Debeir O, De Neve N, Van Damme M, Bontempi G, Haibe-Kains B, Decaestecker C, et al. (2007). 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 9 (5), 358-369.
2. Hashimoto K, Fujita Y, and Iyo M (2007). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 32 (3), 514-521.
3. Stahl SM (2005). Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 10 (4), 319-323.
4. Maurice T, Meunier J, Feng B, Ieni J, and Monaghan DT (2006). Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther 317 (2), 606-614.
5. Brown C, Fezoui M, Selig WM, Schwartz CE, and Ellis JL (2004). Antitussive activity of sigma-1 receptor agonists in the guinea-pig. Br J Pharmacol 141 (2), 233-240.
6. Miller SC (2005). Dextromethorphan psychosis, dependence and physical withdrawal. Addict Biol 10 (4), 325-327.
7. Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, and Hermans E (2004). Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 19 (8), 2212-2220.
8. Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, et al. (2004). Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 64 (14), 4875-4886.
9. Stone JM, Arstad E, Erlandsson K, Waterhouse RN, Ell PJ, and Pilowsky LS (2006). [123I]TPCNE-a novel SPET tracer for the sigma-1 receptor: first human studies and in vivo haloperidol challenge. Synapse 60 (2), 109-117.
10. Cobos EJ, Pozo ED, and Baeyens JM (2007). Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells. J Neurochem [Epub ahead of print] PMID: 17419803.